PTO/SB/68 (09-06)
Approved for use through 3/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	ADAILDOILD ALLEIO	ATION UNDER 37 CFR 1.14
	In re Application of	
ng completed form to		]
e Information ECENTED	Application Number	Filed
ington, /A 22202-3514	09/471349	12/23/99
lephone: (703) 308-2733 2008	7	Paper No. #75
plication, which is not within the file jacke	et of a pending Continued Pro- efit is claimed, in the following	record of the above-identified ABANDONED esecution Application (CPA) (37 CFR 1.53(d)) g document (as shown in the attachment):
United States Patent Number	•	
WIPO Pub. No	, page, line	_
patent application publication, or an Article 21(2), a member of the public originally filed; or any document in the specific or any document in the component of the application is incorporated by registration, a U.S. patent application.	ration Information Retrieval system to allow access to Public PAIR and titled to obtain a copy of all or pay purchased through the Office of ending, a member of the public ration as originally filed; or any do all pending:  I pending:  U.S. patent, or (b) published as international patent application or may obtain a copy of: the file of the pending application reference or otherwise identified on publication, or an international	em (Public PAIR) on the USPTO internet re available in the Public Search Room. art of the application file upon payment of of Public Records upon payment of the may obtain a copy of: ocument in the file of the pending  119(e), 120, 121, or 365 in another a statutory invention registration, a U.S. publication in accordance with PCT contents; the pending application as n.
	P	, ,
N wolon	£	9/30/08
N usdras Signature		9/30/08 Date
HENDRIC		Date  FOR PTO USE ONLY
	<u> </u>	
Typed or printed r	name	
HENDRIC	name	FOR PTO-USE ONLY Approved in CENTED (initials)
Typed or printed r	name  f applicable	FOR PTO-USE ONLY
Typed or printed r	f applicable	FOR PTO-USE ONLY Approved in CENTED (initials)

complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.



(19) United States

## (12) Patent Application Publication (10) Pub. No.: US 2003/0059921 A1

(43) Pub. Date: Mar. 27, 2003

(54) NOVEL CLOT-SPECIFIC STEPTOKINASE PROTEINS POSSESSING ALTERED PLASMINOGEN ACTIVATION CHARACTERISTICS AND A PROCESS FOR THE PREPARATION OF SAID PROTEINS

(75) Inventors: Girish Sahni, Union Territory of Chandigarh (IN); Rajesh Kumar, Union Territory of Chandigarh (IN); Chaiti Roy, Union Territory of Chandigarh (IN); Kammara Rajagopal, Union Territory of Chandigarh (IN); Deepak Nihalani, Union Territory of Chandigarh (IN); Vasudha Sundaram, Union Territory of Chandigarh (IN); Mahavir Yadav, Union Territory of Chandigarh (IN)

> Correspondence Address: JOHN W. FREEMAN, ESQ. Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804 (US)

(73) Assignee: Council of Scientific and Industrial Research of Rafi Marg, a New Delhi, India corporation

(21) Appl. No.: 09/940,235 (22) Filed: Aug. 27, 2001

## Related U.S. Application Data

Continuation of application No (09/471,349, filed on (63)Dec. 23, 1999, now abandoned.

(30)Foreign Application Priority Data

## **Publication Classification**

(51) Int. Cl.<sup>7</sup> ...... C12N 9/64; C07H 21/04; C12P 21/02; C12N 1/21; C12N 5/06 **U.S. Cl.** ...... 435/226; 435/69.1; 435/325; 435/320.1; 536/23.2; 435/252.3

## (57)**ABSTRACT**

Clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.